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Impaired bradykinin response to ischaemia and exercise in
patients with mild congestive heart failure during angiotensin-
converting enzyme treatment. Relationships with endothelial
function, coagulation and inflammation
There is a growing body of evidence indicating that inflam-
mation and endothelial dysfunction play an important role in
the pathophysiology of congestive heart failure (CHF) (Levine
et al, 1990; Testa et al, 1996; Chong et al, 2004), in addition to
the well known neuroendocrine activation including norepi-
nephrine and the renin–angiotensin system (Francis et al,
1990). Inflammation may be detrimental in CHF because
proinflammatory cytokines and chemokines participate
in cardiac depression and progression of heart failure
(Torre-Amione et al, 1996; Kelly & Smith, 1997), and cytokine
levels may be high even before the clinical onset of CHF (Vasan
et al, 2003). However, activation of the kallikrein–kinin
system, which is involved in the inflammatory process and
leads to the production of the vasoactive peptide bradykinin,
may be beneficial in heart failure because bradykinin reduces
arterial resistance, has positive inotropic and lusitropic effects
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Summary
Inflammation and endothelial dysfunction play important roles in the
pathophysiology of congestive heart failure (CHF), and the peptide
bradykinin, generated during inflammation, may act as a defence
mechanism by inducing vasodilation. Plasma bradykinin levels are
increased in experimental heart failure but low in patients with advanced
chronic CHF despite treatment with angiotensin-converting enzyme (ACE)
inhibitors. It is not currently known how bradykinin behaves in less severe
phases of CHF controlled by long-term ACE inhibitor treatment. We studied
10 male patients with clinically stable chronic CHF [New York Heart
Association (NYHA) class II] on long-term ACE inhibitor treatment and 10
normal sex- and age-matched control subjects. High performance liquid
chromatography/radioimmunoassay methods were used to evaluate plasma
levels of bradykinin in relation to an array of parameters of endothelial
function, coagulation and inflammation before and after stimuli of forearm
arterial occlusion and physical exercise. CHF patients had higher levels of
bradykinin (P ¼ 0Æ008), activated factor XII (P ¼ 0Æ049), interleukin-6
(P ¼ 0Æ050) and tumour necrosis factor receptor II (sTNFRII) (P ¼ 0Æ026)
than controls. Arterial occlusion and exercise significantly increased
bradykinin and von Willebrand factor levels in controls but not in CHF
patients. The increase in brachial artery diameter after arterial occlusion was
less in CHF patients (P ¼ 0Æ036) and inversely related to baseline plasma
levels of bradykinin (r ¼ )0Æ855, P ¼ 0Æ002) and sTNFRII (r ¼ )0Æ780,
P ¼ 0Æ008). NYHA class II CHF patients during long-term treatment with
ACE inhibitors have increased bradykinin levels and signs of inflammation.
They are unable to respond adequately to stimuli of ischaemia and physical
exercise which both require vasodilation.
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and decreases myocardial oxygen consumption and ischaemia
(Cheng et al, 1998; Cleland et al, 2000). Bradykinin exerts its
effect through endothelial B2 receptors constitutively expressed
on arteries, and through B1 receptors induced by tissue injury
or proinflammatory cytokines (Prado et al, 2002). Bradykinin
is efficiently degraded by kininases, the most important of
which, in humans, is the angiotensin converting enzyme whose
presence in plasma and on the endothelium represents a link
between the renin–angiotensin and the kallikrein–kinin sys-
tems (Schmaier, 2003).
In dogs, endogenous immunoreactive kinins quadruple after
the acute induction of heart failure by pacing (Cheng et al,
1998), an increase that preserves cardiovascular function and
may partially offset the detrimental effects of activation of the
renin–angiotensin system (Su et al, 1998).
In contrast with the animal model, we found that humans
with advanced CHF have normal plasma bradykinin levels
(Cugno et al, 2000) even in presence of parallel coagulation
activation, endothelial dysfunction and increased proinflam-
matory cytokines levels (Cugno et al, 2000, 2004). No differ-
ences in plasma bradykinin levels were found between the
patients untreated or treated with angiotensin-converting
enzyme (ACE) inhibitors. However, in less severe phases of
CHF controlled by long-term ACE inhibitor therapy, it is not
known how bradykinin behaves in relation to coagulation or
inflammation, and after stimuli, such as ischaemia or physical
exercise (both of which require vasodilation).
In the present investigation, we studied plasma levels of
bradykinin and a series of markers of activation of the kinin
system, coagulation, fibrinolysis and cytokines, as well as
endothelial function, in 10 accurately selected patients with
CHF in stable, functional New York Heart Association
(NYHA) class II during long-term treatment with ACE
inhibitors before and after forearm arterial occlusion as
ischaemic stimulus and physical exercise with a cycle ergom-
eter.
Patients and methods
We studied 10 male patients aged 54–70 years (mean ± SD,
63 ± 6 years) with chronic CHF (NYHA class II) who had
been in a clinical stable condition for at least 3 months and
were receiving optimised treatment, which included diuret-
ics, angiotensin-converting enzyme (ACE)-inhibitors and
beta-blockers. To avoid any interference with treatment, no
patient was on statins, aspirin or other antiplatelet therapy.
All patients were in regular sinus rhythm. The patient’s
clinical characteristics and therapies are shown in Table I.
Ten healthy male subjects age-matched with the patients
served as normal controls. The study was approved by the
local Ethics Committee, and conducted in accordance
with our institutional guidelines and the principles des-
cribed in the Declaration of Helsinki. All of the subjects
gave their written informed consent before taking part in the
study.
Arterial occlusion test
The test was performed in a supine position after a rest of
10 min. An antecubital vein was canulated with a Venflon
catheter 18GA (Becton Dickinson, Helsingborg, Sweden) and a
baseline blood sample was obtained. The brachial artery
diameter was measured on two-dimensional ultrasound ima-
ges, recorded using a 7 MHz linear array transducer and a
standard 125XP/10 system (Acuson, Mountain View, CA,
USA) (Celermajer et al, 1992; Corretti et al, 2002), after which
a sphygmomanometer cuff was inflated to a pressure of
300 mmHg for 3 min. Ninety seconds after cuff deflation, a
second blood sample was obtained and the artery diameter was
re-measured using the artery bifurcation as an anatomic
marker.
Exercise test
Two research exercise tests were performed in a sitting position
on a cycle ergometer: the first test was at a constant workload
exercise of 25-W, and the second test using an individualised
ramp protocol aimed at reaching maximal load within 10 min
(Guazzi et al, 1997). In order to determine the individual ramp
rates for the second test, we used a baseline test to identify each
subject’s maximal oxygen uptake: the patients were encouraged
to exercise until they felt unable to continue because of
dyspnoea or fatigue (symptom-limited maximal exercise).
During the test, the electrocardiogram was continuously
monitored and arterial blood pressure measured by means of
cuff sphygmomanometry. Breath-by-breath analyses of venti-
lation and expiratory gases (CO2 production and O2 con-
sumption) were made at rest and throughout the exercise
period (Sensor Medics 2900 Metabolic Measurement Cart;
Sensor Medics, Yorba Linda, CA, USA). Blood samples were
obtained from an antecubital vein canulated with a Venflon
catheter 18GA under baseline conditions, during constant




Age (years, mean ± SD) 63 ± 6
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Blood pressure (mmHg, mean ± SD)
Systolic 115 ± 10
Diastolic 74 ± 5
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exercise load (6th minute), and at the maximal load. We
performed two research exercise tests to analyse bradykinin,
coagulation and inflammation response to light constant
exercise (below lactic acidosis) and to a maximal exercise
(above lactic acidosis).
Blood sampling
Before and after the two stimulation tests (arterial occlusion
and exercise), blood samples were collected in the morning
into polypropylene tubes containing: (1) sodium citrate
(3Æ8%), to measure the levels of tissue plasminogen activator
(tPA), plasmin–antiplasmin (PAP) complexes, d-dimer frag-
ment, prothrombin fragment F1 + 2, thrombin–antithrombin
(TAT) complexes, fibrinogen, von Willebrand factor (VWF)
antigen, factor VII (FVII), activated factor XII (FXIIa) and
thrombomodulin; (2) ethylenediaminetetraacetic acid sodium
salt (EDTA) to determine the levels of interleukin-6 (IL-6),
tumour necrosis factor alpha (TNF-a), soluble TNF receptor
II (sTNFRII), soluble intercellular adhesion molecule-1 (sI-
CAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-
1) and soluble endothelial selectin (sE-selectin); (3) prechilled
sodium citrate at pH 4Æ3 (Stabilyte; Biopool, Umea, Sweden) for
PAI–1 assay; (4) a cocktail of protease inhibitors (100 mmol/l
trisodium citrate, 67 mmol/l citric acid and 2%dextrose, pH4Æ5,
100 mmol/l benzamidine, 400 lg/ml hexadimethrine bromide,
2 mg/ml soybean trypsin inhibitor, 263 lmol/l leupeptin and
20 mmol/l aminoethylbenzenesulphonylfluoride) to evaluate
cleaved high-molecular-weight kininogen (HK). The samples
were immediately centrifuged at 2000 g, at 4C, aliquoted, frozen
and stored at )80C until testing.
For the bradykinin measurements, blood samples were
collected into prechilled syringes containing a mixture of
protease and peptidase inhibitors to obtain final concentrations
of 21 lmol/l aprotinin, 73 lg/ml chickenegg–albumin trypsin
inhibitor, 305 lg/ml hexadimethrine bromide, 4Æ5 mmol/l
1,10-phenanthroline, and 4Æ5 mmol/l edetic acid. The blood
samples were rapidly transferred into prechilled polypropylene
tubes and centrifuged at 2C. Plasma was immediately precipi-
tated in ethanol and supernatants stored at 80C until analysis.
Measurements
Bradykinin was measured by radioimmunoassay after liquid
phase extraction and high-performance liquid chromatogra-
phy (Nussberger et al, 1998). The method had a detection limit
of 0Æ125 pmol/l and an overall recovery of 99Æ7% (SD 8Æ4%).
Intra- and inter-assay coefficients of variation were 18% at the
low endogenous concentrations.
Activated factor XII (FXIIa) was measured with a sandwich
enzyme-linked immunosorbent assay (ELISA; Asserachrom
FXIIa, Diagnostica Stago, Asnieres, France). The intraassay-
and interassay-coefficients of variation (CV) were less than 7%.
Cleaved high-molecular-weight kininogen (HK) was assessed
by sodium dodecyl sulphate polyacrylamide gel electrophoresis
and immunoblotting analysis. Using this method, native HK
appeared as a band of Mr 130 000 and cleaved HK as two
bands of Mr 107 000 and 98 000. The density of the bands was
evaluated by computerised image analysis (image master;
Pharmacia, Uppsala, Sweden). The amount of cleaved HK
(bands with molecular weights 107 000 and 98 000) was
expressed as a percentage of the total HK (sum of the three
bands) (Cugno et al, 1994).
Thrombin–antithrombin (TAT) complexes were measured
using a sandwich ELISA (Enzygnost TAT Micro; Behring
Diagnostics GmbH, Marburg, Germany). Intraassay- and
interassay-CVs were 2Æ5% and 5%, respectively.
Prothrombin fragment 1 + 2 (F1 + 2) was assessed with a
sandwich ELISA (Enzygnost F1 + 2; Behring Diagnostics
GmbH). Intraassay- and interassay-CVs were 5% and 8%,
respectively.
Factor VII (FVII) antigen was measured by a commercial
ELISA (Asserachrom VII:Ag; Stago) according to the manu-
facturer’s instructions. Intraassay- and interassay-CV were
5Æ2% and 6Æ9%.
Tissue plasminogen activator (tPA) antigen was measured by
a commercial enzyme-linked immunoassay method (Imuno-
lyse tPA; Biopool) according to the manufacturer’s instruc-
tions. Intraassay- and interassay-CVs were 6Æ5% and 8%,
respectively.
Plasminogen activator inhibitor type 1 (PAI-1) antigen was
measured by a commercial ELISA (Innotest PAI-1, Byk
Gulden, Konstanz, Germany). Intraassay- and interassay-CVs
were 8% and 13%, respectively.
Plasmin–antiplasmin (PAP) complexes were measured using
a sandwich ELISA (Enzygnost PAP Micro; Behring Diagnostics
GmbH). Intraassay- and interassay-CV were 3Æ5% and 6Æ5%,
respectively.
d-dimer was measured by a commercial ELISA (Enzygnost
d-dimer; Behring Diagnostics GmbH) according to the
manufacturer’s instructions. Intraassay- and interassay-CVs
were 10% and 15%, respectively.
Von Willebrand factor antigen was measured in citrated
plasma by a sandwich ELISA that used two monoclonal
antibodies directed against different VWF epitopes (11B6Æ18
and 7G10Æ8) (Mannucci & Coppola, 1999). Intraassay- and
interassay-CVs were both lower than 8%.
Thrombomodulin was measured in plasma by a commercial
sandwich ELISA (Asserachrom Thrombomodulin; Diagnostica
Stago). Intraassay- and interassay-CVs were both lower than
10%.
Tumour necrosis factor-a (TNF-a) levels were measured in
plasma by a direct solid-phase immunoassay (Enzyme Ampli-
fied Sensitivity Immunoassay, EASIA; Biosource, Flerus, Bel-
gium). Intraassay- and interassay-CVs were 8% and 10%,
respectively.
Soluble TNF receptor II (sTNFRII) was measured by a
sandwich ELISA (Quantikine Human sTNFRII Immunoassay;
R&D Systems Inc., Minneapolis, MN, USA). Intraassay- and
interassay-CV were 2Æ5% and 5Æ1%, respectively.
Bradykinin and congestive heart failure
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Interleukin-6 (IL-6) was measured in plasma by a sandwich
ELISA (Quantikine Human IL-6 Immunoassay; R&D Systems
Inc.). Intraassay- and interassay-CVs were 4Æ2% and 6Æ4%,
respectively.
Soluble intercellular adhesion molecule-1 (sICAM-1) was
measured in plasma by a sandwich ELISA (Parameter Human
sICAM-1 Immunoassay; R&D Systems Inc.). Intraassay- and
interassay-CV were 4Æ8% and 10Æ1%.
Soluble vascular cell adhesion molecule-1 (sVCAM-1) was
measured in plasma by a sandwich ELISA (Parameter Human
sVCAM-1 Immunoassay; R&D Systems Inc.). Intraassay- and
interassay-CVs were 5Æ9% and 10Æ2%, respectively.
Soluble endothelial selectin (sE-selectin) was measured in
plasma by a sandwich ELISA (Parameter Human sE-selectin
Immunoassay; R&D Systems Inc.). Intraassay- and interassay-
CVs were 5Æ0% and 8Æ8%, respectively.
Statistical analysis
The descriptive statistics are given as mean values ± standard
error of the mean (SEM). Differences between groups were
evaluated by the Student t-test both for unpaired and paired
data. Correlations were assessed by the Pearson test. The




Baseline parameters of the contact system, coagulation,
fibrinolysis and inflammation of patients with CHF are shown
in Table II. Plasma levels of FXIIa and bradykinin were
significantly higher in CHF patients than in controls
(P ¼ 0Æ049 and P ¼ 0Æ008). The markers of inflammation
were also higher in CHF patients than in controls (IL-6,
P ¼ 0Æ05; TNFRII, P ¼ 0Æ026; the differences in TNF-a and C-
reactive protein were not statistically significant) (Table II).
There was no significant difference between the patients and
controls in any of the other parameters.
In CHF patients, plasma levels of bradykinin were signifi-
cantly correlated with levels of FXIIa (r ¼ 0Æ818; P ¼ 0Æ025)
and tPA (r ¼ 0Æ827; P ¼ 0Æ006).
Arterial occlusion test
The brachial artery response to the occlusion test is shown in
Fig 1. Before the stimulation test, brachial artery diameter was
larger in CHF patients (0Æ546 ± 0Æ021 cm) than in controls
(0Æ488 ± 0Æ012 cm) (P ¼ 0Æ028) (the weight and height of the
patients were not significantly different from those of the
Table II. Parameters of contact system, coagu-
lation, fibrinolysis and inflammation in 10








FXIIa (ng/ml) 2Æ76 ± 0Æ44 1Æ67 ± 0Æ22 P ¼ 0Æ049
Cleaved HK (% of total HK) 14Æ9 ± 1Æ6 12Æ6 ± 2Æ9 N.S.
Bradykinin (pmol/l) 13Æ90 ± 2Æ02 6Æ22 ± 1Æ50 P ¼ 0Æ008
FVII antigen (ng/ml) 82 ± 7 96 ± 8 N.S.
F1 + 2 (ng/ml) 0Æ94 ± 0Æ29 0Æ90 ± 0Æ18 N.S.
TAT complexes (ng/ml) 3Æ3 ± 0Æ4 3Æ1 ± 0Æ3 N.S.
VWF (% of normal) 148 ± 27 118 ± 15 N.S.
tPA antigen (ng/ml) 12Æ4 ± 1Æ6 9Æ7 ± 1Æ4 N.S.
PAI-1 antigen (ng/ml) 60 ± 6 66 ± 7 N.S.
PAP complexes (ng/ml) 291 ± 57 206 ± 27 N.S.
d-dimer (ng/ml) 22 ± 5 14 ± 1 N.S.
IL-6 (pg/ml) 7Æ9 ± 2Æ6 2Æ6 ± 1Æ6 P ¼ 0Æ05
TNF (pg/ml) 18Æ2 ± 1Æ1 16Æ2 ± 1Æ1 N.S.
sTNFRII (pg/ml) 3184 ± 525 1892 ± 75 P ¼ 0Æ026
sICAM (ng/ml) 344 ± 47 277 ± 13 N.S.
sVCAM (ng/ml) 645 ± 69 678 ± 58 N.S.
sE-selectin (ng/ml) 60Æ9 ± 9Æ5 42Æ0 ± 5Æ7 N.S.
Thrombomodulin (ng/ml) 40Æ2 ± 10Æ3 37Æ7 ± 6Æ2 N.S.
CRP (lg/l) 2Æ28 ± 0Æ78 1Æ04 ± 0Æ23 N.S.
Mean values ± SEM.
CHF, chronic heart failure; FXIIa, activated factor XII; HK, high molecular weight kininogen;
FVII, factor VII; F1 + 2, prothrombin fragment F1 + 2; TAT, thrombin–antithrombin; VWF,
von Willebrand factor; tPA, tissue type plasminogen activator; PAI, plasminogen activator
inhibitor; PAP, plasmin–antiplasmin; IL-6, interleukin-6; TNF, tumour necrosis factor; sTNFRII,
soluble tumour necrosis factor receptor II; sICAM, soluble intercellular adhesion molecule;
sVCAM, soluble vascular cell adhesion molecule; E-selectin, endothelial-selectin; CRP, C reactive
protein; N.S., not significant.
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controls). After occlusion, the percentage increase was less in
CHF patients (7Æ5 ± 2Æ5%) than in controls (14Æ7 ± 1Æ7%)
(P ¼ 0Æ036).
After stimulation, bradykinin plasma levels significantly
increased in normal subjects (P ¼ 0Æ047) and remained
unchanged high in CHF patients (Fig 2). At the same time,
VWF also increased in normal controls (P ¼ 0Æ021) and
remained unchanged high in CHF patients (Fig 3). All of the
other parameters remained unchanged after arterial occlusion
both in CHF patients and controls.
In our CHF patients, the percentage increase in brachial
artery diameter after the occlusion test was inversely correlated
with the baseline plasma levels of both bradykinin
(r ¼ )0Æ855, P ¼ 0Æ002) (Fig 4) and TNFRII (r ¼ )0Æ780,
P ¼ 0Æ008).
Exercise test
Exercise capacity was significantly lower in our CHF patients.
Peak exercise oxygen consumption (peak VO2) was
2048 ± 422 ml/min in controls and 1352 ± 338 ml/min in
patients (P ¼ 0Æ001); the corresponding weight-corrected
values were 27Æ0 ± 5Æ5 ml/kg/min in controls and
18Æ3 ± 4Æ2 ml/kg/min in patients (P ¼ 0Æ001), which indicated
that our patients were not too seriously compromised.
In normal controls, the exercise test induced an increase in
plasma bradykinin levels after both constant (P ¼ 0Æ05) and
maximal load (P ¼ 0Æ07), but a decrease in the CHF patients
(P ¼ 0Æ04 and P ¼ 0Æ015 respectively, Fig 5). Two markers of
endothelial stimulation (VWF and tPA) increased in normal
controls during the exercise test: VWF was significantly
increased after both constant and maximal load (Fig 6),
whereas tPA was increased only after maximal load (from
11Æ9 ± 1Æ3 to 16Æ2 ± 2Æ1 ng/ml, P ¼ 0Æ01). In contrast, the
levels of both VWF and tPA remained unchanged in the CHF
patients.
Fig 1. Brachial artery diameter expressed as centimetre in 10 normal
controls and in 10 patients with chronic congestive heart failure (CHF)
before and after the arterial occlusion test.
Fig 2. Bradykinin plasma levels expressed as pmol/l in 10 normal
controls and in 10 patients with chronic congestive heart failure (CHF)
before and after the arterial occlusion test.
Fig 3. Plasma levels of von Willebrand factor expressed as percentage
of normal in 10 normal controls and in 10 patients with chronic
congestive heart failure (CHF) before and after the arterial occlusion
test.
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Discussion
The results of our study show that CHF patients (NYHA class
II) undergoing long-term ACE inhibitor treatment have high
plasma bradykinin levels. After ischaemic and physical exercise
stimuli, plasma levels of bradykinin and endothelial markers
increased in normal subjects but not in CHF patients, whose
endothelial-dependent vasodilation was reduced and inversely
correlated with the levels of bradykinin and the sensitive
inflammation marker TNFRII.
The small number of patients in our study was chosen
because a large series of tests was to be carried out to
simultaneously compare the involvement of the contact
system, coagulation, fibrinolysis, inflammation and endothelial
function. Our patients were accurately selected to have a
clinically stable condition and a well standardised long-term
treatment with ACE inhibitors, diuretics and low-dose beta-
blockers.
Before the stimulation tests, the high bradykinin levels of
our CHF patients significantly correlated with the plasma levels
of FXIIa, a sensitive marker of contact system activation.
Bradykinin is physiologically generated during contact system
activation as a result of the action on HK of kallikrein, an
enzyme derived from the zymogen prekallikrein as a result of
the action of FXIIa, and which in turn activates FXII to FXIIa
(Kaplan et al, 2002). Thus our data indicate that the increase
in bradykinin may be because of activation of the contact
system. Our CHF patients also had slightly increased cleaved
HK levels, however the sensitivity of the method we used for
measuring HK (Western blot analysis) was low and even a very
small cleavage of HK could generate the femtomols of
bradykinin that were clearly detected by the bradykinin assay.
The observed direct correlation between bradykinin and tPA
may be because of the fact that bradykinin induces tPA release
from human endothelium via a B2 receptor-dependent, NO
synthase-independent and cyclooxygenase-independent path-
way, as previously demonstrated by Brown et al (2000).
High bradykinin levels have been previously described after
measuring immunoreactive kinins in animal models of pacing-
induced heart failure (Cheng et al, 1998) and, in these models,
bradykinin exerted vasodilator effects (Su et al, 1998). Bra-
dykinin was also involved in the beneficial effects of ACE
inhibition on ejection fraction, heart volumes and remodelling
in rats with CHF induced by myocardial infarction (Liu et al,
Fig 4. Correlation between baseline plasma levels of bradykinin (ex-
pressed as pmol/l) and brachial artery diameter increase after the
occlusion test (expressed as percentage increase) in 10 patients with
chronic congestive heart failure. The Pearson’s correlation coefficient
‘r’ is reported.
Fig 5. Plasma levels of bradykinin expressed as pmol/l in 10 normal
controls and in 10 patients with chronic congestive heart failure (CHF)
under baseline conditions and during the exercise test after constant
load and maximal load.
Fig 6. Plasma levels of von Willebrand factor expressed as percentage
of normal in 10 normal controls and in 10 patients with chronic
congestive heart failure (CHF) under baseline conditions and during
the exercise test after constant load and maximal load.
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2000). A number of studies of patients with heart failure, using
bradykinin receptor antagonists, have shown that bradykinin
contributes to the haemodynamic effects of ACE inhibition
(Witherow et al, 2001; Fujii et al, 2002; Cruden et al, 2004). So
far, our group (Cugno et al, 2000) and Duncan et al (2000)
have directly measured the bradykinin 1–9 peptide in CHF
patients. We found that chronic CHF patients in NYHA class
III and IV have normally low bradykinin levels (about 2 pmol/
l) even when they are taking ACE inhibitors (Cugno et al,
2000), and Duncan et al (2000) also found a bradykinin
concentration of 2 pmol/l in the arterial blood of severe heart
failure patients taking ACE inhibitors.
In the present study, in patients with CHF in NYHA class II
during treatment with ACE inhibitor, we found that the
concentrations of bradykinin were clearly high (13Æ9 pmol/l).
The difference in bradykinin concentrations between the
present and previous studies may be because of the different
severity of CHF, and we therefore hypothesise that the increase
in bradykinin acts as a defence mechanism that is active in the
less severe phases of heart failure, but disappears with the
progression of the disease. It is interesting to note that, before
occlusion, the diameter of the brachial artery in CHF patients
was larger than in controls (Fig 1), which is in line with the
vasodilating effect of the increased levels of bradykinin. After
arterial occlusion, the increase in brachial artery diameter was
less in the CHF patients than in normal controls and, unlike
the increase observed in the controls, the bradykinin levels of
the patients remained unchanged (Fig 2). This suggests that
the kinin system is activated or bradykinin catabolism is
reduced in CHF patients and that they can no longer respond
adequately to the ischaemic stimulus. This view is further
supported by the inverse correlation between baseline plasma
bradykinin levels and the percentage increase in brachial artery
diameter after the occlusion test (Fig 4).
The postocclusion increase in brachial artery diameter also
inversely correlated with baseline plasma levels of TNFRII, one
of the most sensitive markers of inflammation. Our CHF
patients had higher levels of inflammation markers than
controls, and this may contribute to endothelial dysfunction.
In a model of human umbilical vein endothelial cells, Agnoletti
et al (1999) demonstrated endothelial dysfunction induced by
CHF patient serum that is partially antagonised by anti-TNF
antibodies. Moreover, Fichtlscherer et al (2001) showed
impaired systemic endothelial vasodilatory capacity in patients
with advanced heart failure, which was improved by the anti-
TNF drug, etanercept. Endothelial involvement in our CHF
patients was also supported by plasma levels of the endothelial
marker VWF, which were higher in CHF patients than in
normal controls and did not increase after the ischaemic
stimulus (Fig 3). We did not observe the activation of
coagulation described in patients with advanced CHF (Cugno
et al, 2004), but there was a slight, non-significant increase in
the markers of coagulation activation.
Plasma bradykinin levels were increased by physical exercise
in normal subjects and reduced in CHF patients, who thus
showed a defect in an exercise-related vasodilatory mechanism
(Fig 5). The high levels of bradykinin in normal controls after
exercise, similar to the baseline levels in CHF patients, could be
because of contact system activation and/or reduced bradyk-
inin metabolisation. It should be noted that the lack of
exercise-induced vasodilation in CHF patients was observed
both below (constant workload exercise) and above the
anaerobic threshold (peak exercise of a ramp protocol). The
bradykinin response at peak exercise might be influenced by
the different workload achieved by controls and patients.
However, in CHF patients, the same impairment of the
bradykinin response to exercise was observed with both
maximal and constant workload exercise, and the latter was
performed at the same load (25 W) in patients and controls.
This weakens the hypothesis that the intensity of exercise was
the major cause of the differences observed between CHF
patients and controls.
The reduced endothelial response to exercise in CHF was
also supported by the finding that plasma levels of VWF and
tPA (two endothelial markers) remained unchanged after
exercise in the patients while they significantly increased in the
normal controls (Fig 6). The effects of exercise on VWF and
tPA in normal subjects are well known (Paton et al, 2004) and
a defect in exercise-induced VWF release that could be
normalised by physical training has recently been observed in
CHF patients (Sabelis et al, 2004). Concerning bradykinin,
ours is the first study evaluating the response to exercise in
CHF patients to demonstrate not only the absence of an
increase in bradykinin levels, but also a significant decrease in
contrast to the significant bradykinin increase observed in
normal controls. The latter may represent a vasodilating
defence mechanism during physical exercise, as hypothesised
more than 20 years ago by James and Donaldson (1981).
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